Board Change • Feb 13
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 7 experienced directors. No highly experienced directors. Interim CEO & Director Jean-Luc Vandebroek is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. お知らせ • Oct 28
BioSenic S.A. Announces Executive Changes BioSenic S.A. announced that In October 2024, Carole Nicco stepped down from her roles as Chief Scientific and Operations Officer of BioSenic to focus on the subsidiary Medsenic SAS. お知らせ • Sep 17
Véronique Pomi-Schneiter Step Down as BioSenic's Deputy CEO BioSenic announced that Véronique Pomi-Schneiter resignes for personal reasons as Deputy CEO of BioSenic. Véronique Pomi-Schneiter will fully assist in the transition process and continue to serve as non-executive member of the board of directors of BioSenic, as well as an executive member of the board of directors (i.e., the strategic committee) of its subsidiary, Medsenic SAS. お知らせ • Jan 10
Biosenic S.A. and Its Subsidiary Medsenic SAS Announces the Promotion of Carole Nicco to Chief Operating Officer BioSenic S.A. and its subsidiary Medsenic SAS announces the promotion of Dr. Carole Nicco to Chief Operating Officer (COO) in addition to her position as Chief Scientific Officer (CSO). Dr. Carole Nicco will be involved in the strategic planning, decision-making and management of key initiatives, as well as overseeing and enhancing the strategic development of BioSenic's pipelines, targeting treatments with its visco supplementation, cell therapy and arsenic trioxide platforms. She will work closely with BioSenic's CEO, Prof. François Rieger, to further oversee and enhance BioSenic's strategic decisions. Dr. Nicco has already begun to meet and interact with key global players interested in the development of the global BioSenic project or targeted therapeutic innovations. BioSenic wishes her all due success in her new commitments in company. お知らせ • Jan 27
BioSenic S.A. Appoints Yves Sagot as Independent Director BioSenic announced the appointment of Yves Sagot as a Member of the Board and Independent Director. Yves co-founded Relief Therapeutics in 2013 to develop a clinical asset acquired from Merck Serono. In 2016, Relief Therapeutics went public on the Swiss stock exchange (SIX) after a reverse merger with THERAMetrics. Whilst maintaining his activities as Chief Scientific Officer at Relief Therapeutics, Yves created MBS Sagot Consulting in 2018 to provide to the life science market senior expertise covering research and early clinical development. Subsequently, after leaving Relief Therapeutics, he is a private investor in biotechnology via MBS Invest & Consult Sàrl. He is also one of the ambassadors of the Léon Bérard Cancer Center. He has authored 25 papers that have been published in international peer-reviewed journals, holds three granted patents and received the Serono CEO Award in 2001 and the Merck Serono Reward and Recognition Award in 2008. Yves Sagot replaces Terry Sadler as an Independent Director and Member of the Board at BioSenic.Yves Sagot has been appointed to the BioSenic Board for his experience and achievements for Relief Therapeutics SA and a number of specific aspects that mirror recent BioSenic developments. お知らせ • Jan 18
BioSenic Appoints Dr. Carole Nicco as Chief Scientific Officer BioSenic announced it is strengthening its scientific team with the appointment of Dr. Carole Nicco, as Chief Scientific Officer (CSO). Dr. Carole Nicco will be responsible for managing the company’s scientific research and development. She will work closely with the company’s CEO, Prof. François Rieger, to further supervise and enhance the company’s strategic pipeline development, targeting treatments with its cell therapy and autoimmune disease platforms. Dr. Nicco brings more than two decades of expertise in cancer biology and immunology, inflammation, immunity, new target identification and drug discovery. Prior to joining the company, Dr. Nicco has actively conducted programs from research all the way through to preclinical trials in collaboration with renown pharma companies (Vertex, BOIRON, IPRAD/GYNOV, Medsenic). Additionally, she has directed dozens of preclinical studies for pathologies ranging from cancer to endometriosis, as well as in autoimmune diseases (SLE, SSc, cGVHD) or pathologies implicating the immune system, including wound healing, uveitis, sepsis, hepatitis and endometriosis. From 2005 to 2023, Carole was one of the principle investigators and the lab manager of the research team Pathogeny andinnovative treatments for chronic fibro-inflammatory diseases at Cochin Institute, a biomedical research center affiliated with INSERM (Unit 1016), CNRS (UMR 8104) and Paris Cité University. She was also head of the conventional preclinical structure of the Cochin Institute for the 10 last years. Since 2016, Dr. Nicco is a member of the scientific committee and advisory board of four international congresses: Paris Redox, Targeting Mitochondria, Targeting Microbiota and Skin Challenges. In 2023, Dr. Nicco becomes President of the international non-profit organization Redox Medecine Society (previous International Society of Antioxidants in Nutrition and Health). She is the author of 110 articles published in international scientific journals in the fields of autoimmune disorders, inflammation and cancer. Dr. Nicco holds a Ph.D. in human physiology and physiopathology from Denis Diderot University of Paris, France.